A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults
NCT ID: NCT05262179
Last Updated: 2022-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
16 participants
INTERVENTIONAL
2021-10-05
2022-07-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001
NCT05017870
Safety and Tolerability of NTX-101 in Korean Healthy Volunteers
NCT05041543
Phase 1 Study for Safety and Tolerability of HL036
NCT02717208
Study Evaluating Safety of BT01001 Ophthalmic Solution
NCT07313722
Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial
NCT05353101
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CTO0101
CTO0101
1 drop/ once or three times a day/ for 17 days divided into stage2
Placebo (Vehicle)
Placebo (vehicle)
1 drop/ once or three times a day/ for 17 days divided into stage2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CTO0101
1 drop/ once or three times a day/ for 17 days divided into stage2
Placebo (vehicle)
1 drop/ once or three times a day/ for 17 days divided into stage2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent to participate in the trial
Exclusion Criteria
* Smokers with an average daily smoking amount exceeding 10 cigarettes
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taejoon Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Taejoon Pharmaceutical Co., Ltd.
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTO0101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.